Research Article: Antibody–drug conjugates in ovarian cancer
Introduction:
More than a century ago Paul Ehrlich, the winner of the Nobel Price of Medicine in 1908, had the vision to link a cytotoxic payload to a factor with selective affinity to the pathogen, this concept was also known as “the magic bullet”. Antibody–drug conjugates (ADCs) seem to have the potential to implement this vision into modern cancer treatment; they are formed by three main components: (I) a therapeutic monoclonal antibody, (II) a potent cytotoxic agent (payload) and (III) a spacer arm as linker [1]. Owing to…
Read more